ZYBER PHARMACEUTICALS INC. – Trademark Portfolio

Entity Type: 03

ZYBER PHARMACEUTICALS INC. holds 22 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 22 filings in this category. The owner is based in Gonzales, LA.

P.O. Box 40

Gonzales, LA 70707

22 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

TUSSINAC
TUSSINAC
Cancelled 2009
ZEMA-PAK
ZEMA-PAK
Cancelled 2009
NAZYNE
NAZYNE
Abandoned 2008
QUINZYME
QUINZYME
Cancelled 2008
REZYST
REZYST
Cancelled 2008
Z-PRO
Z-PRO
Abandoned 2008
INFAHIST
INFAHIST
Abandoned 2007
INFATUSS
INFATUSS
Abandoned 2007
BROVEX
BROVEX
Cancelled 2007
ENCINTA
ENCINTA
Abandoned 2006
NODOLOR
NODOLOR
Cancelled 2006
COCO-COF
COCO-COF
Cancelled 2006
FOLQUID
FOLQUID
Abandoned 2005
ZOLTEX
ZOLTEX
Abandoned 2005
BROVEX
BROVEX
Cancelled 2002
ALDEX
ALDEX
Cancelled 2002
ZYNEX
ZYNEX
Abandoned 2001
Z-COF
Z-COF
Cancelled 2001
PEDIATEX
PEDIATEX
Cancelled 1999

Trademark Classifications

ZYBER PHARMACEUTICALS INC.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (22 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does ZYBER PHARMACEUTICALS INC. have?

ZYBER PHARMACEUTICALS INC. has 22 U.S. trademarks filed with the USPTO.

What trademark classes does ZYBER PHARMACEUTICALS INC. file in?

ZYBER PHARMACEUTICALS INC. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What is ZYBER PHARMACEUTICALS INC.'s trademark registration success rate?

ZYBER PHARMACEUTICALS INC. has a 0% trademark registration rate, with 0 out of 22 resolved applications resulting in successful registration. Currently, 0 applications are pending review.